HK1006059A1 - Risperidone pamoate - Google Patents

Risperidone pamoate

Info

Publication number
HK1006059A1
HK1006059A1 HK98105164A HK98105164A HK1006059A1 HK 1006059 A1 HK1006059 A1 HK 1006059A1 HK 98105164 A HK98105164 A HK 98105164A HK 98105164 A HK98105164 A HK 98105164A HK 1006059 A1 HK1006059 A1 HK 1006059A1
Authority
HK
Hong Kong
Prior art keywords
pct
risperidone
sec
compositions
compound
Prior art date
Application number
HK98105164A
Other languages
English (en)
Inventor
Jean Louis Mesens
Jozef Peeters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1006059A1 publication Critical patent/HK1006059A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
HK98105164A 1993-04-28 1998-06-11 Risperidone pamoate HK1006059A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93201216 1993-04-28
PCT/EP1994/001296 WO1994025460A1 (en) 1993-04-28 1994-04-22 Risperidone pamoate

Publications (1)

Publication Number Publication Date
HK1006059A1 true HK1006059A1 (en) 1999-02-05

Family

ID=8213799

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98105164A HK1006059A1 (en) 1993-04-28 1998-06-11 Risperidone pamoate

Country Status (32)

Country Link
US (2) US5612346A (zh)
EP (1) EP0697019B1 (zh)
JP (1) JP3478397B2 (zh)
KR (1) KR100307101B1 (zh)
CN (1) CN1041727C (zh)
AT (1) ATE163418T1 (zh)
AU (1) AU675136B2 (zh)
BG (1) BG62004B1 (zh)
CA (1) CA2160366C (zh)
CY (1) CY2107B1 (zh)
CZ (1) CZ286688B6 (zh)
DE (1) DE69408666T2 (zh)
DK (1) DK0697019T3 (zh)
ES (1) ES2113652T3 (zh)
FI (1) FI109125B (zh)
GR (1) GR3026028T3 (zh)
HK (1) HK1006059A1 (zh)
HU (1) HU218212B (zh)
IL (1) IL109448A (zh)
LV (1) LV12315B (zh)
NO (1) NO305083B1 (zh)
NZ (1) NZ266143A (zh)
PH (1) PH30476A (zh)
PL (1) PL182466B1 (zh)
RO (1) RO115955B1 (zh)
RU (1) RU2131428C1 (zh)
SG (1) SG47046A1 (zh)
SI (1) SI9420031B (zh)
SK (1) SK280589B6 (zh)
TW (1) TW376319B (zh)
WO (1) WO1994025460A1 (zh)
ZA (1) ZA942909B (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100354270B1 (ko) 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
CA2304568C (en) * 1997-09-30 2008-08-12 Eli Lilly And Company Olanzapine pamoate formulations
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN1146422C (zh) * 1998-09-30 2004-04-21 伊莱利利公司 2-甲基-噻吩并-苯并二氮杂�制剂
EP1129094A2 (en) * 1998-11-12 2001-09-05 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1534288A1 (en) * 2002-08-23 2005-06-01 Ranbaxy Laboratories, Ltd. Stable aqueous solutions of risperidone and methods for their preparation
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
WO2004094415A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1708790B1 (en) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
PL1838716T3 (pl) * 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
MY152789A (en) * 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
EP2234617B1 (en) * 2007-12-19 2021-03-31 Janssen Pharmaceutica NV Dosing regimen associated with long acting injectable paliperidone esters
HRP20240285T1 (hr) 2011-03-18 2024-05-24 Alkermes Pharma Ireland Limited Farmaceutski pripravci koji sadrže sorbitan estere
EP2702060B1 (en) * 2011-04-26 2015-12-30 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
WO2013150052A1 (en) 2012-04-04 2013-10-10 Intervet International B.V. Soft chewable pharmaceutical products
CN102659577B (zh) * 2012-04-07 2014-07-02 安徽绩溪县徽煌化工有限公司 一种亚甲基双羟基萘酸的制备方法
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
AU2013322612B2 (en) 2012-09-26 2017-06-01 Tangent Reprofiling Limited Modulators of androgen synthesis
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 可乐定双羟萘酸盐及其制备方法
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
KR100307101B1 (ko) 2001-11-30
AU675136B2 (en) 1997-01-23
ZA942909B (en) 1995-10-26
ATE163418T1 (de) 1998-03-15
EP0697019A1 (en) 1996-02-21
CN1121719A (zh) 1996-05-01
CA2160366C (en) 2006-06-06
HUT72970A (en) 1996-06-28
PL182466B1 (pl) 2002-01-31
US5612346A (en) 1997-03-18
HU218212B (hu) 2000-06-28
BG100094A (bg) 1996-05-31
RU2131428C1 (ru) 1999-06-10
DK0697019T3 (da) 1998-09-28
WO1994025460A1 (en) 1994-11-10
CN1041727C (zh) 1999-01-20
DE69408666D1 (de) 1998-04-02
NO305083B1 (no) 1999-03-29
CZ286688B6 (en) 2000-06-14
NO954275L (no) 1995-10-26
AU6721694A (en) 1994-11-21
FI109125B (fi) 2002-05-31
LV12315A (lv) 1999-07-20
CA2160366A1 (en) 1994-11-10
BG62004B1 (bg) 1998-12-30
JP3478397B2 (ja) 2003-12-15
FI955166A (fi) 1995-10-27
SI9420031A (en) 1996-08-31
RO115955B1 (ro) 2000-08-30
SK131395A3 (en) 1996-06-05
ES2113652T3 (es) 1998-05-01
PL311282A1 (en) 1996-02-05
DE69408666T2 (de) 1998-06-18
EP0697019B1 (en) 1998-02-25
PH30476A (en) 1997-05-28
HU9501934D0 (en) 1995-09-28
US5723467A (en) 1998-03-03
LV12315B (en) 2000-03-20
FI955166A0 (fi) 1995-10-27
JPH08509482A (ja) 1996-10-08
SG47046A1 (en) 1998-03-20
TW376319B (en) 1999-12-11
IL109448A (en) 1997-03-18
GR3026028T3 (en) 1998-04-30
CZ270695A3 (en) 1996-01-17
SK280589B6 (sk) 2000-04-10
NZ266143A (en) 1996-07-26
CY2107B1 (en) 2002-04-26
SI9420031B (sl) 2002-08-31
IL109448A0 (en) 1994-07-31
NO954275D0 (no) 1995-10-26

Similar Documents

Publication Publication Date Title
CY2107B1 (en) Risperidone pamoate
FR05C0045I2 (zh)
HK1002017A1 (en) Lyospheres comprising gonadotropin
HUT72974A (en) Polypeptide and anti-hiv agent prepared therefrom
ES2104386T3 (es) Compuesto intermedio para la acitromicina.
GB9126725D0 (en) Process
TW261516B (zh)
ZA939227B (en) Novel triazoloquinazolines,their preparation and use
AU1466592A (en) Gem-diphosphonic acid nitrosocarbamoyl derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
AU675281B2 (en) Application of riluzole as a radiorestorer

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20140421